Discovery of Resorcinol-Based Polycyclic Structures as Tyrosinase Inhibitors for Treatment of Parkinson’s Disease-Reference-Cited by-同舟云学术

Discovery of Resorcinol-Based Polycyclic Structures as Tyrosinase Inhibitors for Treatment of Parkinson’s Disease

Published:2021-12-09 Issue:1 Volume:13 Page:81-96
ISSN:1948-7193
Container-title:ACS Chemical Neuroscience
language:en
Short-container-title:ACS Chem. Neurosci.

Author:

Li Qi¹,Mo Jun²,Xiong Baichen³,Liao Qinghong⁴,Chen Ying⁴,Wang Yuanyuan³,Xing Shuaishuai³,He Siyu⁵,Lyu Weiping⁵,Zhang Ning⁴,Sun Haopeng³^ORCID

Affiliation:

1. Department of Medical Pharmacy, School of Basic Medicine, Qingdao University, Qingdao 266071, People’s Republic of China

2. ZJU-ENS Joint Laboratory of Medicinal Chemistry, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, People’s Republic of China

3. School of Pharmacy, China Pharmaceutical University, Nanjing 211198, People’s Republic of China

4. Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, People’s Republic of China

5. School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China

Publisher

American Chemical Society (ACS)

Subject

Cell Biology,Cognitive Neuroscience,Physiology,Biochemistry,General Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acschemneuro.1c00560

Reference53 articles.

1. Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments

2. Ageing and Parkinson's disease: Why is advancing age the biggest risk factor?